Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database
Maria Chiara Rossi,Riccardo Bonfanti,Giusi Graziano,Monica Larosa,Fortunato Lombardo,Antonio Nicolucci,Giacomo Vespasiani,Stefano Zucchini,Ivana Rabbone,G. P. Bracciolini,V. Cherubini,A. Bobbio,S. Zucchini,T. Suprani,V. De Donno,F. Lombardo,R. Bonfanti,A. Franzese,I. Rabbone,V. Graziani,M. Zampolli,I. Rutigliano,L. de Sanctis,L. P. Guerraggio,R. Franceschi,G. Tornese,F. Franco,C. Maffeis,C. Arnaldi,the ISPED CARD Study Group
DOI: https://doi.org/10.1007/s00592-024-02304-2
2024-05-26
Acta Diabetologica
Abstract:Aims Glargine 300 U/mL (Gla-300) has been recently approved for use in children and adolescents with type 1 diabetes (T1D). However, real-world effectiveness data are scarce, and aim of this analysis was to assess clinical outcomes in young patients with T1D switching from 1st generation basal insulin (1BI) to Gla-300. Methods ISPED CARD is a retrospective, multicenter study, based on data anonymously extracted from Electronic Medical Records. The study involved a network of 20 pediatric diabetes centers. Data on all patients aged < 18 years with T1D switching from 1BI to Gla-300 were analyzed to assess clinical characteristics at the switch and changes after 6 and 12 months in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), and standardized body mass index (BMI/SDS). Titration of basal and short-acting insulin doses was also evaluated. Results Overall, 200 patients were identified. The mean age at the switch to Gla-300 was 13 years, and mean duration of diabetes was 3.9 years. Average HbA1c levels at switch were 8.8%. After 6 months, HbA1c levels decreased by − 0.88% (95% CI − 1.28; − 0.48; p < 0.0001). The benefit was maintained after 12 months from the switch (mean reduction of HbA1c levels − 0.80%, 95% CI − 1.25; − 0.35, p = 0.0006). Trends of reduction in FBG levels were also evidenced both at 6 months and 12 months. No significant changes in short-acting and basal insulin doses were documented. Conclusions The study provides the first real-world evidence of the effectiveness of Gla-300 in children and adolescents with T1D previously treated with 1BI. The benefits in terms of HbA1c levels reduction were substantial, and sustained after 12 months. Additional benefits can be expected by improving the titration of insulin doses.
endocrinology & metabolism